UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2011
______________________ RBC Life Sciences, Inc. ______________________
(Exact name of registrant as specified in its charter)
_______ NEVADA _______
(State or other jurisdiction
of incorporation)
_______ 000-50417 _________
(Commission
File Number)
_______ 91-2015186 ________
(IRS Employer
Identification No.)
2301 CROWN COURT, IRVING, TEXAS
(Address of principal executive offices)
____________ 75038 _____________
(Zip Code)
Registrant's telephone number, including area code __________ 972-893-4000 ______________
__________________________ N/A ____________________________
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 2.02 Results of Operations and Financial Condition .

On November 9, 2011 , RBC Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2011 . A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, this information, including the exhibit related hereto, is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No.      Description
99.1
Press release dated November 9, 2011 announcing financial results for the quarter ended September 30, 2011 .




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 9, 2011

                            
RBC Life Sciences, Inc.
By: /s/ Steven E. Brown
Name: Steven E. Brown
Title: Chief Financial Officer









Exhibit Index

Exhibit Number
Description
99.1
Press release dated November 9, 2011, announcing financial results for the quarter ended September 30, 2011
    





EXHIBIT 99.1

RBC Life Sciences ®  

Press Release
For Further Information:
For Immediate Release
Steve Brown, Executive EVP, CFO
Tel: 972-893-4000
steve.brown@rbclifesciences.com
RBC Life Sciences Reports Third Quarter Results

Irving, Texas, November 9, 2011 - RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, wound care and pain management products, today reported an increase in consolidated net sales of 15% for the third quarter of 2011. Net sales for the quarter ended September 30, 2011 were $7.1 million compared to net sales of $6.1 million for the same quarter in 2010. For the third quarter of 2011, the Company also reported a net loss of $290,000, or $0.01 per share, compared to net earnings of $133,000, or $0.01 per share, for the same quarter last year. Net sales were $21.1 million and $20.9 million for the nine months ended September 30, 2011 and 2010, respectively, while the net loss for the nine months ended September 30, 2011 was $129,000, or $0.01 per share, compared to net earnings of $517,000, or $0.02 per share the comparable period in 2010.
“Net sales in our Associate network channel have been very positive this year growing 54% during the first nine months of 2011. We continue to see strong sales results for our new product, Stem-Kine TM , and new Associate growth in excess of 100%,” said RBC Life Sciences President and CEO, Clinton H. Howard. “The net loss in the third quarter resulted mainly from investments we made in a new branch office in Taiwan, which opened October 1, 2011, a Company-sponsored leadership event for the top achievers in our Associate network and expansion of our Medical Products sales force."

Stem-Kine is a dietary supplement that has been shown in published human clinical studies to nutritionally enable bone marrow and other stem cell-producing tissues to increase their production of stem cells, which form the natural repair and renewal system of the body. The Company distributes Stem-Kine under an exclusive license agreement that covers the U.S. and 41 other countries.
About RBC Life Sciences
Through wholly owned subsidiaries , RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical , the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's website at www.rbclifesciences.com .

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

Contacts:
Steve Brown
972-893-4000
steve.brown@rbclifesciences.com




RBC Life Sciences - Third Quarter 2011
Page 2

RBC Life Sciences, Inc.
Summary Results of Operations
(in thousands, except per share data)
(unaudited)

Quarters Ended September 30,
2011
2010
Net sales
$
7,061

$
6,126

Gross profit
3,318

3,290

Operating profit (loss)
(486
)
171

Earnings (loss) before income taxes
(521
)
133

Provision (benefit) for income taxes
(231
)
—

Net earnings (loss)
(290
)
133

Earnings (loss) per share - basic
$
(0.01
)
$
0.01

Earnings (loss) per share - diluted
$
(0.01
)
$
0.01

Weighted average shares outstanding - basic
22,229

21,922

Weighted average shares outstanding - diluted
22,229

22,469


Nine Months Ended September 30,
2011
2010
Net sales
$
21,093

$
20,946

Gross profit
10,619

10,335

Operating profit (loss)
(167
)
928

Earnings (loss) before income taxes
(274
)
813

Provision (benefit) for income taxes
(145
)
296

Net earnings (loss)
(129
)
517

Earnings (loss) per share - basic
$
(0.01
)
$
0.02

Earnings (loss) per share - diluted
$
(0.01
)
$
0.02

Weighted average shares outstanding - basic
22,229

21,922

Weighted average shares outstanding - diluted
22,229

22,386







RBC Life Sciences - Third Quarter 2011
Page 3
RBC Life Sciences, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

September 30,
December 31,
2011
2010
Assets
Cash and cash equivalents
$
4,720

$
4,220

Inventories
6,782

5,343

Other current assets
1,823

1,696

Total current assets
13,325

11,259

Other assets
6,807

7,085

Total assets
$
20,132

$
18,344

Liabilities and shareholders' equity
Accounts payable and accrued liabilities
$
3,709

$
3,087

Deferred revenue
3,862

2,490

Other current liabilities
179

168

Total current liabilities
7,750

5,745

Other liabilities
2,596

2,723

Shareholders' equity
9,786

9,876

Total liabilities and shareholders' equity
$
20,132

$
18,344




EDGAR Online, Inc. and the information providers herein make no claims concerning the validity of the information provided hereby and will not be held liable for any use of this information. The information provided herein may be displayed and printed for your internal use only and may not reproduced, retransmitted, distributed, disseminated, sold, published, broadcast or circulated to anyone without the express written consent of EDGAR Online, Inc.